Results 61 to 70 of about 822 (144)

Saroglitazar and vitamin E vs. lifestyle interventions in metabolic dysfunction associated steatotic liver disease: A 3-arm randomised study. [PDF]

Indian J Med Res
Tiwari AK, Singh G, Kumar V, Yadav DP, Shukla SK, Singh V, Mishra G, Tiwary NK, Anunay A, Singh D, Chaturvedi D.   +10 more
europepmc   +1 more source

Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial. [PDF]

Indian J Med Res
Bhagat N, De A, Duseja A, C P G, Kumar M, Mehta M, Taneja S, Sahni N, Singh V.   +8 more
europepmc   +1 more source

Comparative Efficacy of Pioglitazone, Saroglitazar, and Silymarin on Biochemical and Histopathological Hepatic Outcomes in a Wistar Rat Model of Non-alcoholic Fatty Liver Disease and Their Correlation With Insulin Sensitivity. [PDF]

Cureus
Jain I, Nath R, Kumar M, Pal R, Dixit R.
europepmc   +1 more source

Effectiveness and Safety of Saroglitazar in Patients With Metabolic Disease in India Stratified by Estimated Glomerular Filtration Rate (eGFR): A Retrospective, Observational, Electronic Medical Record (EMR)-Based Real-World Evidence Study. [PDF]

Cureus
Tripathi K, Chafekar D, Verma H, Bantwal G, Shah P, Bhattacharya S, Sahay M, Golay V, G S, Awasthi R, Jaiswal A, Mudaliyar V, Jhaveri KS, G J, Shah S, Verma G.   +15 more
europepmc   +1 more source

A Study to Evaluate the Effect of Saroglitazar in Type 2 Diabetes

International Journal of Contemporary Medical Research [IJCMR], 2019
Jaswant Goyal, Sudhir Bhandari, Sengupta Kushan Kaushik, Barkha Goyal, Saloni Cahandali, Rashmi Attri   +5 more
openaire   +1 more source

Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease. [PDF]

Front Pharmacol
Li X, Zhang J, Wei B, Tong H.
europepmc   +1 more source

Saroglitazar: the World’s First Drug for Treating Diabetic Dyslipidemia

Journal of Comprehensive Pharmacy, 2014
Krishna Undela, Manohar Gopal
openaire   +1 more source

A Comparative Evaluation of the Effects of Saroglitazar and Pioglitazone on Hepatic and Metabolic Parameters in Type 2 Diabetes Mellitus With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). [PDF]

Cureus
Meher D, Das S, Choudhury A, Sahoo D, Sahu SK, Agarwal V, Prusty B, Ketan Das B, Chappalagavi AS, Gupta S, Sreekumar V.   +10 more
europepmc   +1 more source

Role of Saroglitazar in Improving Transient Elastography Parameters in Significant and Advanced Metabolic Dysfunction-Associated Steatohepatitis. [PDF]

Cureus
Kak MC.
europepmc   +1 more source

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis. [PDF]

Aliment Pharmacol Ther
Schattenberg JM, Banales JM, Hirschfield G, Trivedi P, Cable EE, McWherter CA, Billin AN, Crittenden DB, Budas G.   +8 more
europepmc   +1 more source